179 related articles for article (PubMed ID: 26813590)
1. [Reversal of stemness in multidrug-resistant hepatocellular carcinoma cells by SIS3].
Yan W; Wen T; Lin S; Liu Z; Yang W; Wu G
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):731-5. PubMed ID: 26813590
[TBL] [Abstract][Full Text] [Related]
2. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
3. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
4. [Metformin induces apoptosis in hepatocellular carcinoma Huh-7 cells in vitro and its mechanism].
Lin F; Yan W; Wen T; Wu GY
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):742-6. PubMed ID: 24378094
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.
Yan F; Wang XM; Pan C; Ma QM
World J Gastroenterol; 2009 Mar; 15(12):1443-51. PubMed ID: 19322916
[TBL] [Abstract][Full Text] [Related]
7. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
8. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
[TBL] [Abstract][Full Text] [Related]
9. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
[TBL] [Abstract][Full Text] [Related]
10. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells.
Yan F; Wang XM; Liu ZC; Pan C; Yuan SB; Ma QM
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):287-95. PubMed ID: 20525557
[TBL] [Abstract][Full Text] [Related]
11. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
12. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
13. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells.
Chen Y; Yu D; Zhang H; He H; Zhang C; Zhao W; Shao RG
Int J Biol Sci; 2012; 8(7):992-1004. PubMed ID: 22904667
[TBL] [Abstract][Full Text] [Related]
14. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-induced senescence promotes stemness and tumorigenicity in EpCAM-/CD133- nonstem cell population in hepatocellular carcinoma cell line, HuH-7.
Karabicici M; Alptekin S; Fırtına Karagonlar Z; Erdal E
Mol Oncol; 2021 Aug; 15(8):2185-2202. PubMed ID: 33524223
[TBL] [Abstract][Full Text] [Related]
16. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
17. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
18. EGF reverses multi-drug resistance via the p-ERK pathway in HepG2/ADM and SMMC7721/ADM hepatocellular carcinoma models.
Yan F; Bai LP; Gao H; Zhu CM; Lin L; Kang XP
Asian Pac J Cancer Prev; 2014; 15(6):2619-23. PubMed ID: 24761873
[TBL] [Abstract][Full Text] [Related]
19. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
